(NASDAQ: GPCR) Structure Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.
Structure Therapeutics's earnings in 2026 is -$141,202,000.On average, 17 Wall Street analysts forecast GPCR's earnings for 2026 to be -$372,387,071, with the lowest GPCR earnings forecast at -$464,453,090, and the highest GPCR earnings forecast at -$295,452,863. On average, 15 Wall Street analysts forecast GPCR's earnings for 2027 to be -$459,586,258, with the lowest GPCR earnings forecast at -$608,162,791, and the highest GPCR earnings forecast at -$365,309,974.
In 2028, GPCR is forecast to generate -$473,655,441 in earnings, with the lowest earnings forecast at -$637,321,280 and the highest earnings forecast at -$361,505,768.